239 related articles for article (PubMed ID: 15508059)
1. Esophagitis in an adolescent patient with Crohn's disease after changing treatment from prednisolone to budesonide.
Weigand K; Wagner-Thiessen E; Stolte M
Z Gastroenterol; 2004 Oct; 42(10):1179-81. PubMed ID: 15508059
[TBL] [Abstract][Full Text] [Related]
2. A comparison of budesonide with prednisolone for active Crohn's disease.
Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
[TBL] [Abstract][Full Text] [Related]
3. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
[TBL] [Abstract][Full Text] [Related]
4. Budesonide for Crohn's disease.
Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
[TBL] [Abstract][Full Text] [Related]
5. Oral budesonide in the management of Crohn's disease.
Hofer KN
Ann Pharmacother; 2003 Oct; 37(10):1457-64. PubMed ID: 14519035
[TBL] [Abstract][Full Text] [Related]
6. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
Escher JC;
Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):47-54. PubMed ID: 15095852
[TBL] [Abstract][Full Text] [Related]
7. Influence of topically and systemically active steroids on circulating leukocytes in Crohn's disease.
Tillinger W; Gasche C; Reinisch W; Lichtenberger C; Bakos S; Dejaco C; Moser G; Vogelsang H; Gangl A; Lochs H
Am J Gastroenterol; 1998 Oct; 93(10):1848-53. PubMed ID: 9772043
[TBL] [Abstract][Full Text] [Related]
8. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
Sandborn WJ; Feagan BG; Lichtenstein GR
Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
[TBL] [Abstract][Full Text] [Related]
9. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
Hanauer S; Sandborn WJ; Persson A; Persson T
Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
[TBL] [Abstract][Full Text] [Related]
10. Budesonide modified-release capsules.
Baker DE
Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
[TBL] [Abstract][Full Text] [Related]
11. Rhabdomyolysis due to severe hypokaliemia in a Crohn's disease patient after budesonide treatment.
Mangone M; Spagnolo A; Capurso G; Marignani M; Panzuto F; Angeletti S; Ruggeri M; Menè P; Delle Fave G
Dig Liver Dis; 2007 Aug; 39(8):776-9. PubMed ID: 17049941
[TBL] [Abstract][Full Text] [Related]
12. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
McKeage K; Goa KL
Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
[TBL] [Abstract][Full Text] [Related]
13. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
[TBL] [Abstract][Full Text] [Related]
14. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study.
Tursi A; Giorgetti GM; Brandimarte G; Elisei W; Aiello F
Med Sci Monit; 2006 Jun; 12(6):PI29-32. PubMed ID: 16733496
[TBL] [Abstract][Full Text] [Related]
15. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
[TBL] [Abstract][Full Text] [Related]
16. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
Lichtenstein GR; Bengtsson B; Hapten-White L; Rutgeerts P
Aliment Pharmacol Ther; 2009 Mar; 29(6):643-53. PubMed ID: 19035972
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease.
Abreu MT
Nat Clin Pract Gastroenterol Hepatol; 2005 May; 2(5):210-1. PubMed ID: 16265201
[No Abstract] [Full Text] [Related]
18. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.
Schoon EJ; Bollani S; Mills PR; Israeli E; Felsenberg D; Ljunghall S; Persson T; Haptén-White L; Graffner H; Bianchi Porro G; Vatn M; Stockbrügger RW;
Clin Gastroenterol Hepatol; 2005 Feb; 3(2):113-21. PubMed ID: 15704045
[TBL] [Abstract][Full Text] [Related]
19. Budesonide in Crohn's disease: findings of a compassionate-use program.
Lyckegaard E; Håkansson K; Bengtsson B
Hepatogastroenterology; 2007; 54(79):2024-7. PubMed ID: 18251152
[TBL] [Abstract][Full Text] [Related]
20. Crohn's disease of the esophagus.
Davidson JT; Sawyers JL
Am Surg; 1983 Mar; 49(3):168-72. PubMed ID: 6830072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]